

June 20, 2019

Daniel E. Greenleaf  
Chief Executive Officer  
BioScrip, Inc.  
1600 Broadway  
Suite 700  
Denver, CO 80202

Re: BioScrip, Inc.  
Preliminary Proxy Statement on Schedule 14A  
Filed April 30, 2019  
File No. 001-11993

Dear Mr. Greenleaf:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Corporation Finance  
Apparel and

Sincerely,  
Division of  
Office of Beverages,  
Mining